<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412025000400123</article-id>
<article-id pub-id-type="doi">10.24245/gom.v93i4.9449</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[El parche anticonceptivo transdérmico; revisión narrativa del estado actual de sus usos]]></article-title>
<article-title xml:lang="en"><![CDATA[The transdermal contraceptive patch; Narrative review of the current state of its uses.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rosales Ortiz]]></surname>
<given-names><![CDATA[Sergio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Velázquez Ramírez]]></surname>
<given-names><![CDATA[Norma]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Campos Goenaga]]></surname>
<given-names><![CDATA[Zigor]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chapa Krueger]]></surname>
<given-names><![CDATA[Alejandro Mauricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Córdova González]]></surname>
<given-names><![CDATA[Roberto Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Corona López]]></surname>
<given-names><![CDATA[Rodolfo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guerrero Carreño]]></surname>
<given-names><![CDATA[Francisco Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Huerta Casillas]]></surname>
<given-names><![CDATA[Félix Rafael]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santoyo Haro]]></surname>
<given-names><![CDATA[Samuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Médica Sur  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Secretaría de Salud  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital de Ginecoobstetricia 4 Dr. Luis Castelazo Ayala ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Doctors Hospital AUNA  ]]></institution>
<addr-line><![CDATA[Monterrey Nuevo León]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,OCA Medical Center  ]]></institution>
<addr-line><![CDATA[Monterrey Nuevo León]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Secretaría de Salud  ]]></institution>
<addr-line><![CDATA[Guadalajara Jalisco]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Hospital Ángeles Lindavista  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Hospital Pablo Neruda  ]]></institution>
<addr-line><![CDATA[Zapopan Jalisco]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,Hospital Ángeles Pedregal  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>93</volume>
<numero>4</numero>
<fpage>123</fpage>
<lpage>134</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412025000400123&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412025000400123&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412025000400123&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  OBJETIVO: Describir el estado actual del uso del parche anticonceptivo transdérmico.  METODOLOGÍA: Revisión bibliográfica efectuada en dos bases de datos: PubMed y Google Scholar de artículos publicados del 2001 al 2023, en idioma inglés y español, utilizando los términos MeSH: transdermal contraception, contraceptive patch, norelgestromin and ethinyl estradiol. Los artículos los seleccionaron y analizaron nueve ginecoobstetras para una revisión narrativa, enmarcada en seis preguntas.  RESULTADOS: Se encontraron 84 artículos de anticoncepción con norelgestromina y etinilestradiol, en presentación de parche transdérmico. Se eliminaron 17. De los 67 artículos seleccionados: 17 fueron de revisión, 49 ensayos clínicos y una guía de práctica clínica.  CONCLUSIONES: El parche transdérmico anticonceptivo es una intervención farmacológica con efectividad anticonceptiva y múltiples acciones terapéuticas, similares a las de otros hormonales combinados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  OBJECTIVE: To describe the current state of use of the transdermal contraceptive patch.  METHODOLOGY: Bibliographic review performed in two databases: PubMed and Google Scholar of articles published from 2001 to 2023, in English and Spanish, using MeSH terms: "transdermal contraception, contraceptive patch, norgestromin and ethinyl estradiol". The articles were selected and analyzed by nine obstetrician-gynecologists for a narrative review using six questions.  RESULTS: 84 articles were found on contraception with norgestromin and ethinyl estradiol in the form of a transdermal patch. 17 were eliminated. Of the 67 articles selected; (: 17 were review articles, 49 were clinical trials, and one was a clinical practice guideline.  CONCLUSIONS: The transdermal contraceptive patch is a pharmacological intervention with contraceptive efficacy and multiple therapeutic actions, similar to those of other combined hormonal contraceptives.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Anticoncepción transdérmica]]></kwd>
<kwd lng="es"><![CDATA[parche anticonceptivo]]></kwd>
<kwd lng="es"><![CDATA[norelgestromina]]></kwd>
<kwd lng="es"><![CDATA[etinilestradiol]]></kwd>
<kwd lng="en"><![CDATA[Transdermal contraception]]></kwd>
<kwd lng="en"><![CDATA[Contraceptive patch]]></kwd>
<kwd lng="en"><![CDATA[Norelgestromin]]></kwd>
<kwd lng="en"><![CDATA[Ethinyl estradiol]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Comisión Económica para América Latina y el Caribe (CEPAL)</collab>
<collab>Observatorio Demográfico</collab>
<source><![CDATA[(LC/PUB.2022/13-P), Santiago]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<source><![CDATA[Planificación Familiar/ métodos anticonceptivos OMS Datos y Cifras]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<source><![CDATA[ENADID Resultados 2014]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<source><![CDATA[ENADID Resultados 2018]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<source><![CDATA[Food and Drug Administration. Approval Letter: Ortho-Evra (NDA #021-180)]]></source>
<year>2001</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>Comparativo venta total anual global EVRA</collab>
<source><![CDATA[Datos auditados Gedeon Richter plc]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<source><![CDATA[Situación de la Salud Sexual y Reproductiva]]></source>
<year>2016</year>
<publisher-name><![CDATA[República Mexicana CONAPO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meneses]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ailines]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[MF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores que influyen en el conocimiento funcional de métodos anticonceptivos, 2014]]></article-title>
<source><![CDATA[La situación demográfica de México 2017]]></source>
<year>2018</year>
<page-range>65-92</page-range><publisher-name><![CDATA[Consejo Nacional de Población]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abrams]]></surname>
<given-names><![CDATA[D. Skee]]></given-names>
</name>
<name>
<surname><![CDATA[K]]></surname>
<given-names><![CDATA[Talluri]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bioavailability of 17-deacetylnorgestimate (17D-NGM) and ethinyl estradiol (EE) from a contraceptive patch]]></article-title>
<source><![CDATA[FASEB J]]></source>
<year>2000</year>
<volume>14</volume>
<page-range>A1479</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dittrich]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rosen]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ortho Evra/Evra 001 Study Group. Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2002</year>
<volume>186</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15-20</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galzote]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Rafie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Teal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transdermal delivery of combined hormonal contraception: a review of the current literature]]></article-title>
<source><![CDATA[Int J Womens Health]]></source>
<year>2017</year>
<volume>9</volume>
<page-range>315-21</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burkman]]></surname>
<given-names><![CDATA[RT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The transdermal contraceptive system]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2004</year>
<volume>190</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>S49-53</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burkman]]></surname>
<given-names><![CDATA[RT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transdermal hormonal contraception: benefits and risks]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2007</year>
<volume>197</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>134.e1-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goa]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Warner]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
<name>
<surname><![CDATA[Easthope]]></surname>
<given-names><![CDATA[SE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception]]></article-title>
<source><![CDATA[Treat Endocrinol]]></source>
<year>2003</year>
<volume>2</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>191-206</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pierson]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Archer]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Moreau]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2003</year>
<volume>80</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>34-42</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dittrich]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rosen]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ortho Evra/Evra 001 Study Group. Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2002</year>
<volume>186</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15-20</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abrams]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Skee]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Natarajan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetic overview of Ortho Evra/Evra]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2002</year>
<volume>77</volume>
<numero>2^s2</numero>
<issue>2^s2</issue>
<supplement>2</supplement>
<page-range>S3-12</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<collab>Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit</collab>
<collab>New Product Review</collab>
<article-title xml:lang=""><![CDATA[Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra)]]></article-title>
<source><![CDATA[J Fam Plann Reprod Health Care]]></source>
<year>2003</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>43-5</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernandez-Juarez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Latorre]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno-Hernandez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic effects of the contraceptive skin patch and subdermal contraceptive implant in Mexican women: a prospective study]]></article-title>
<source><![CDATA[Reprod Health]]></source>
<year>2014</year>
<volume>11</volume>
<page-range>33</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graziottin]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A review of transdermal hormonal contraception: focus on the ethinylestradiol/norelgestromin contraceptive patch]]></article-title>
<source><![CDATA[Treat Endocrinol]]></source>
<year>2006</year>
<volume>5</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>359-65</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smallwood]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Meador]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Lenihan]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ORTHO EVRA/EVRA 002 Study Group. Efficacy and safety of a transdermal contraceptive system]]></article-title>
<source><![CDATA[Obstet Gynecol]]></source>
<year>2001</year>
<volume>98</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>799-805</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Creasy]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Abrams]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[AC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transdermal contraception]]></article-title>
<source><![CDATA[Semin Reprod Med]]></source>
<year>2001</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>373-80</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nelson]]></surname>
<given-names><![CDATA[AL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transdermal contraception methods: today&amp;apos;s patches and new options on the horizon]]></article-title>
<source><![CDATA[Expert Opin Pharmacother]]></source>
<year>2015</year>
<volume>16</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>863-73</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jakimiuk]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Crosignani]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Chernev]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High levels of women&amp;apos;s satisfaction and compliance with transdermal contraception: results from a European multinational, 6-month study]]></article-title>
<source><![CDATA[Gynecol Endocrinol]]></source>
<year>2011</year>
<volume>27</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>849-56</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[Kaunitz]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Laguardia]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial]]></article-title>
<source><![CDATA[Obstet Gynecol]]></source>
<year>2005</year>
<volume>105</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1389-96</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bustillos-Alamilla]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Zepeda-Zaragoza]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Ruiz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticoncepción con hormonales combinados en ciclos extendidos artificialmente [Combined hormonal contraception in cycles artificially extended]]]></article-title>
<source><![CDATA[Ginecol Obstet Mex]]></source>
<year>2010</year>
<volume>78</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>37-45</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lavelanet]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Rybin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[KO.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The pharmacokinetics of 12-week continuous contraceptive patch use]]></article-title>
<source><![CDATA[Contraception]]></source>
<year>2017</year>
<volume>95</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>578-85</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zieman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Guillebaud]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Weisberg]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2002</year>
<volume>77</volume>
<numero>2^s2</numero>
<issue>2^s2</issue>
<supplement>2</supplement>
<page-range>S13-8</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<collab>Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. New Product Review</collab>
<article-title xml:lang=""><![CDATA[Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra)]]></article-title>
<source><![CDATA[J Fam Plann Reprod Health Care]]></source>
<year>2003</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>43-5</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Grimes]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Gallo]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Skin patch and vaginal ring versus combined oral contraceptives for contraception]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2013</year>
<volume>2013</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>CD003552</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Audet]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Moreau]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Koltun]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2001</year>
<volume>285</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>2347-54</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crosignani]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Nappi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ronsini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Italian EVRA Contrast Study Group. Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women&amp;apos;s experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy]]></article-title>
<source><![CDATA[BMC Womens Health]]></source>
<year>2009</year>
<volume>30</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>18</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weisberg]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bouchard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Moreau]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NRGEEP-CON-401 Study Group. Preference for and satisfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study]]></article-title>
<source><![CDATA[J Obstet Gynaecol Can]]></source>
<year>2005</year>
<volume>27</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>350-9</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Archer]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Cullins]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Creasy]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy]]></article-title>
<source><![CDATA[Contraception]]></source>
<year>2004</year>
<volume>69</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>189-95</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Archer]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Bigrigg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Smallwood]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2002</year>
<volume>77</volume>
<numero>2^s2</numero>
<issue>2^s2</issue>
<supplement>2</supplement>
<page-range>S27-31</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abrams]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Skee]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Natarajan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants]]></article-title>
<source><![CDATA[Contraception]]></source>
<year>2001</year>
<volume>64</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>287-94</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zacur]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Hedon]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mansour]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2002</year>
<volume>77</volume>
<numero>2^s2</numero>
<issue>2^s2</issue>
<supplement>2</supplement>
<page-range>S32-5</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piyasirisilp]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Taneepanichskul]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A clinical study of transdermal contraceptive patch in Thai adolescence women]]></article-title>
<source><![CDATA[J Med Assoc Thai]]></source>
<year>2008</year>
<volume>91</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>137-41</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abrams]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Skee]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches]]></article-title>
<source><![CDATA[J Clin Pharmacol]]></source>
<year>2001</year>
<volume>41</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1232-7</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abrams]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Skee]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Natarajan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise]]></article-title>
<source><![CDATA[J Clin Pharmacol]]></source>
<year>2001</year>
<volume>41</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1301-9</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graziottin]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety, efficacy and patient acceptability of the combined estrogen and progestin transdermal contraceptive patch: a review]]></article-title>
<source><![CDATA[Patient Prefer Adherence]]></source>
<year>2008</year>
<volume>2</volume>
<page-range>357-67</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O&amp;aposConnell K]]></surname>
<given-names><![CDATA[Burkman RT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The transdermal contraceptive patch: an updated review of the literature]]></article-title>
<source><![CDATA[Clin Obstet Gynecol]]></source>
<year>2007</year>
<volume>50</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>918-26</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gruber]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sk&#345;ivánek]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Serrani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study]]></article-title>
<source><![CDATA[Contraception]]></source>
<year>2015</year>
<volume>91</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>105-12</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sibai]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Odlind]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Meador]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparative and pooled análisis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra)]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2002</year>
<volume>77</volume>
<numero>2^s2</numero>
<issue>2^s2</issue>
<supplement>2</supplement>
<page-range>S19-26</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suwanmalee]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Taneepanichskul]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A clinical study of transdermal contraceptive patch in Thai women]]></article-title>
<source><![CDATA[J Med Assoc Thai]]></source>
<year>2006</year>
<volume>89</volume>
<numero>^s4</numero>
<issue>^s4</issue>
<supplement>4</supplement>
<page-range>S1-4</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanga]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vaughan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nangosyah]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life]]></article-title>
<source><![CDATA[Int J Clin Pharmacol Ther]]></source>
<year>2022</year>
<volume>60</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>67-78</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parasrampuria]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Vaughan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ariyawansa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of a transdermal contraceptive patch with a newly sourced adhesive component versus EVRA patch: A double-blind, randomized, bioequivalence and adhesion study in healthy women]]></article-title>
<source><![CDATA[Contraception]]></source>
<year>2020</year>
<volume>101</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>276-82</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jick]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Kaye]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Russmann]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol]]></article-title>
<source><![CDATA[Contraception]]></source>
<year>2006</year>
<volume>73</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>223-8</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jick S]]></surname>
<given-names><![CDATA[Kaye JA]]></given-names>
</name>
<name>
<surname><![CDATA[Li L]]></surname>
<given-names><![CDATA[al]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol]]></article-title>
<source><![CDATA[Contraception]]></source>
<year>2007</year>
<volume>76</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-7</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keenan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kerr]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Duane]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic Review of Hormonal Contraception and Risk of Venous Thrombosis]]></article-title>
<source><![CDATA[Linacre Q]]></source>
<year>2018</year>
<volume>85</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>470-7</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sidney]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cheetham]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Connell]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users]]></article-title>
<source><![CDATA[Contraception]]></source>
<year>2013</year>
<volume>87</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>93-100</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heikinheimo]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Toffol]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Partonen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic hormonal contraception and risk of venous thromboembolism]]></article-title>
<source><![CDATA[Acta Obstet Gynecol Scand]]></source>
<year>2022</year>
<volume>101</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>846-55</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Creasy]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile]]></article-title>
<source><![CDATA[J Reprod Med]]></source>
<year>2003</year>
<volume>48</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>179-86</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zieman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Guillebaud]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Weisberg]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2002</year>
<volume>77</volume>
<numero>2^s2</numero>
<issue>2^s2</issue>
<supplement>2</supplement>
<page-range>S13-8</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burkman]]></surname>
<given-names><![CDATA[RT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The transdermal contraceptive patch: a new approach to hormonal contraception]]></article-title>
<source><![CDATA[Int J Fertil Womens Med]]></source>
<year>2002</year>
<volume>47</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>69-76</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abrams]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Skee]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Natarajan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2002</year>
<volume>53</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>141-6</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fleischer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[van Vliet]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Rosendaal]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study]]></article-title>
<source><![CDATA[Thromb Res]]></source>
<year>2009</year>
<volume>123</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>429-35</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maguire]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Westhoff]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The state of hormonal contraception today: established and emerging noncontraceptive health benefits]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2011</year>
<volume>205</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>S4&#8208;S8</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kiley]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hammond]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combined oral contraceptives: a comprehensive review]]></article-title>
<source><![CDATA[Clin Obstet Gynecol]]></source>
<year>2007</year>
<volume>50</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>868-77</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<collab>FSRH Guideline</collab>
<article-title xml:lang=""><![CDATA[Combined Hormonal Contraception (Revision due by January 2024)]]></article-title>
<source><![CDATA[BMJ Sex Reprod Health]]></source>
<year>2019</year>
<volume>45</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>1-93</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murillo-Zamora]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mendoza-Cano]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Guzmán-Esquivel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends in Teen Births in Mexico Spanning 25 Years: A Need for Regionally-directed Preventive Strategies]]></article-title>
<source><![CDATA[Arch Med Res]]></source>
<year>2019</year>
<volume>50</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>142-50</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chabbert-Buffet]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Marret]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Agostini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical practice guidelines for contraception by the French National College of Gynecologists and Obstetricians (CNGOF)]]></article-title>
<source><![CDATA[J Gynecol Obstet Hum Reprod]]></source>
<year>2019</year>
<volume>48</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dokras]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Noncontraceptive use of oral combined hormonal contraceptives in polycystic ovary syndrome-risks versus benefits]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2016</year>
<volume>106</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1572-9</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Stanczyk]]></surname>
<given-names><![CDATA[FZ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of oral versus transdermal steroidal contraceptives on androgenic markers]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2005</year>
<volume>192</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2055-9</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Requena]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Llombart]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral Contraceptives in Dermatology]]></article-title>
<source><![CDATA[Actas Dermosifiliogr (Engl Ed)]]></source>
<year>2020</year>
<volume>111</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>351-6</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harper]]></surname>
<given-names><![CDATA[JC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of Oral Contraceptives for Management of Acne Vulgaris: Practical Considerations in Real World Practice]]></article-title>
<source><![CDATA[Dermatol Clin]]></source>
<year>2016</year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>159-65</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arowojolu]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
<name>
<surname><![CDATA[Gallo]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Grimes]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combined oral contraceptive pills for treatment of acne]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2004</year>
<numero>3</numero>
<issue>3</issue>
<page-range>CD004425</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vercellini]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Barbara]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Somigliana]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2010</year>
<volume>93</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2150-61</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Grimes]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Schulz]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Steroidal contraceptives: effect on bone fractures in women]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2006</year>
<volume>4</volume>
<page-range>CD006033</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Massaro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Di Carlo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gargano]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study]]></article-title>
<source><![CDATA[Contraception]]></source>
<year>2010</year>
<volume>81</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>209-14</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xia]]></surname>
<given-names><![CDATA[YY]]></given-names>
</name>
<name>
<surname><![CDATA[Gronwald]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Karlan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hereditary Ovarian Cancer Clinical Study Group. Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2022</year>
<volume>164</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>514-21</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maxwell]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Schildkraut]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Calingaert]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2006</year>
<volume>103</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>535-40</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vogler]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Patterson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kamemoto]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188]]></article-title>
<source><![CDATA[J Acquir Immune Defic Syndr]]></source>
<year>2010</year>
<volume>55</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>473-82</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pietrzak]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bobrowska]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Jabiry-Zieniewicz]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral and transdermal hormonal contraception in women after kidney transplantation]]></article-title>
<source><![CDATA[Transplant Proc]]></source>
<year>2007</year>
<volume>39</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2759-62</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ozel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins]]></article-title>
<source><![CDATA[Contraception]]></source>
<year>2006</year>
<volume>74</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>293-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
